Lipid Management in 2015: Risk & Controversies Michael Miller, MD R. Michael Benitez, MD.

23
Lipid Management in 2015: Risk & Controversies Michael Miller, MD R. Michael Benitez, MD

Transcript of Lipid Management in 2015: Risk & Controversies Michael Miller, MD R. Michael Benitez, MD.

Page 1: Lipid Management in 2015: Risk & Controversies Michael Miller, MD R. Michael Benitez, MD.

Lipid Management in 2015:Risk & Controversies

Michael Miller, MDR. Michael Benitez, MD

Page 2: Lipid Management in 2015: Risk & Controversies Michael Miller, MD R. Michael Benitez, MD.

2013 ACC/AHA Guidelines• Emphasis on statins as first-line

therapy due to strong body of supporting evidence

• Focus on ‘appropriate intensity’ statin therapy in 3 groups ‘most likely to benefit’

2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Stone NJ, et al. Circulation 2013; JACC 2013

Page 3: Lipid Management in 2015: Risk & Controversies Michael Miller, MD R. Michael Benitez, MD.

#1 - Clinical Atherosclerotic CVD

• History of CAD, MI, stable/unstable angina

• Coronary or other arterial revascularization

• CVA / TIA• Peripheral arterial disease

Page 4: Lipid Management in 2015: Risk & Controversies Michael Miller, MD R. Michael Benitez, MD.

#2 - LDL > 190 mg/dl• Targeting familial

hypercholesterolemia

Page 5: Lipid Management in 2015: Risk & Controversies Michael Miller, MD R. Michael Benitez, MD.

#3 - Diabetic, age 40-75, LDL 70-189

• Calculate 10 year risk of atherosclerotic CVD

• If Risk > 7.5% High-Intensity statin• If Risk < 7.5%, moderate-intensity

statin– Lowers LDL 30-50%– Atorva 10-20, rosuva 5-10, simva 20-

40, prava 40-80, lova 40, pitava 2 – 4

Page 6: Lipid Management in 2015: Risk & Controversies Michael Miller, MD R. Michael Benitez, MD.
Page 7: Lipid Management in 2015: Risk & Controversies Michael Miller, MD R. Michael Benitez, MD.

10 Year ASCVD Risk: Pooled Cohort Equation

• Demographics– Age (40-79)– Gender– Race

• History– HTN– DM– Tobacco

• Measurements– Tchol– HDL– Systolic BP

Page 8: Lipid Management in 2015: Risk & Controversies Michael Miller, MD R. Michael Benitez, MD.

Estimated 10 year risk >7.5%

• The guidelines state that the risk estimator does not, and should not determine which patients receive statins

• Statin use should be determined after a ‘detailed risk discussion’ between patient and physician

Page 9: Lipid Management in 2015: Risk & Controversies Michael Miller, MD R. Michael Benitez, MD.

Case 1• Tom is a 55 year old African American

man• He had a NSTEMI at age 50, with

subsequent PCI of the LAD. • He is on atorvastatin 80 mg/daily,

along with aspirin, beta-blocker and ACE-i.

Page 10: Lipid Management in 2015: Risk & Controversies Michael Miller, MD R. Michael Benitez, MD.

• “Should I get my cholesterol checked?”

Page 11: Lipid Management in 2015: Risk & Controversies Michael Miller, MD R. Michael Benitez, MD.

Tom’s labs• TChol - 170 mg/dl• Triglycerides - 140 mg/dl• HDL Chol - 42 mg/dl• LDL Chol - 90 mg/dl

Page 12: Lipid Management in 2015: Risk & Controversies Michael Miller, MD R. Michael Benitez, MD.

Questions• Should we still follow levels?• How often should we follow levels?• The current guidelines are very

focused on statin therapy . . .• What is the role of non-statin therapy

for elevated LDL cholesterol?

Page 13: Lipid Management in 2015: Risk & Controversies Michael Miller, MD R. Michael Benitez, MD.

Case 2• Tom’s older brother, aged 60, comes

to see you.• He had CABG at age 52, is a never-

smoker, but has hypertension and type II diabetes, with a hemoglobin A1c of 7%.

• He shops with Tom, and they are both on Atorvastatin 80 mg daily. He is on no other lipid lowering medicine.

Page 14: Lipid Management in 2015: Risk & Controversies Michael Miller, MD R. Michael Benitez, MD.

• His cholesterol values:– TChol - 164 mg/dl– HDL Chol - 28 mg/dl– LDL Chol - 70 mg/dl– Triglycerides (fasting) - 280 mg/dl

Page 15: Lipid Management in 2015: Risk & Controversies Michael Miller, MD R. Michael Benitez, MD.

Questions?• Should he be treated

with another agent for his elevated triglycerides?

• Should he receive any treatment targeted towards the low HDL cholesterol?

Page 16: Lipid Management in 2015: Risk & Controversies Michael Miller, MD R. Michael Benitez, MD.

Case 3• Tom’s younger brother, age 50, also

comes to see you.• He is asymptomatic and has no known

history of CAD, but he is worried that both of this older brothers had serious heart disease at about his age.

• He is a ‘never-smoker’, and is not hypertensive or diabetic.

• Tchol 220 / HDL 44 / SBP 132 mm Hg

Page 17: Lipid Management in 2015: Risk & Controversies Michael Miller, MD R. Michael Benitez, MD.
Page 18: Lipid Management in 2015: Risk & Controversies Michael Miller, MD R. Michael Benitez, MD.

Questions?• How do we account for FAMILY

HISTORY under the new guidelines?• Should he be treated?• What is the role of further testing?– Coronary calcium scoring?– Hi-sensitivity CRP?

Page 19: Lipid Management in 2015: Risk & Controversies Michael Miller, MD R. Michael Benitez, MD.

• He undergoes Coronary Calcium CT scoring; Agatston score of 28, all RCA

Page 20: Lipid Management in 2015: Risk & Controversies Michael Miller, MD R. Michael Benitez, MD.

Questions?• Does this establish him as having

CAD?• Should he be treated with statin? Hi

dose? Moderate dose? (what should the target of treatment be - and how should this be followed?)

Page 21: Lipid Management in 2015: Risk & Controversies Michael Miller, MD R. Michael Benitez, MD.

All in the Family• Tom’s mother comes to see you.• She has no history of CAD. She is

hypertensive, not diabetic, has never smoked and is not symptomatic.

• She is 80 years old.

Page 22: Lipid Management in 2015: Risk & Controversies Michael Miller, MD R. Michael Benitez, MD.

Questions?

• What is the role of statin therapy in the elderly ...– for Primary

Prevention?– for Secondary

Prevention?

Page 23: Lipid Management in 2015: Risk & Controversies Michael Miller, MD R. Michael Benitez, MD.

How Low Should We Go?

53 yo Woman with newly diagnosed CAD

Prior to statin:

TC=86

TG= 27

HDL= 35

LDL= 46She was placed on Atorvastatin 80 mg w/o symptoms.

Do you continue same or modify regimen?